|
Market Closed -
Nasdaq
23:00:00 27/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 28.85 USD | +1.69% |
|
+12.96% | +9.57% |
| 05:20pm | Zymeworks Inc. - Special Call | |
| 10-24 | Zymeworks Inc. Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate Zw191 At ESMO Congress 2026 | CI |
| Market Cap | 2.01B 1.81B 1.67B 1.51B 2.83B 191B 2.86B 20B 7.94B 100B 7.56B 7.39B 318B | P/E 2026 * |
31.6x | P/E 2027 * | 38x |
|---|---|---|---|---|---|
| Enterprise Value | 1.77B 1.59B 1.46B 1.33B 2.48B 168B 2.51B 17.56B 6.97B 87.97B 6.63B 6.49B 279B | EV / Sales 2026 * |
6.02x | EV / Sales 2027 * | 4.61x |
| Free-Float |
92.05% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ZYME | Delayed | |
CBOE
| ZYME | Real-time | |
|
Tradegate
| ZA8 | Real-time | |
|
Boerse Muenchen
| ZA8 | Real-time | |
|
Deutsche Boerse AG
| ZA8 | Delayed | |
|
Börse Stuttgart
| ZA8 | Delayed |
Last Transcript: Zymeworks Inc.
| 1 day | +1.69% | ||
| 1 week | +12.96% | ||
| Current month | +8.91% | ||
| 1 month | +8.79% | ||
| 3 months | +26.20% | ||
| 6 months | +2.67% | ||
| Current year | +9.57% |
| 1 week | 26.9 |  | 29.18 |
| 1 month | 24.6 | | 29.18 |
| Current year | 21.52 | | 31.34 |
| 1 year | 16 | | 31.34 |
| 3 years | 6.69 | | 31.34 |
| 5 years | 4.11 | | 31.34 |
| 10 years | 4.11 | | 59.03 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ken Galbraith
CEO | Chief Executive Officer | 63 | 05/01/2022 |
Kristin Stafford
DFI | Director of Finance/CFO | 44 | 01/04/2026 |
Robert Yamamoto
CTO | Chief Tech/Sci/R&D Officer | - | 01/12/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Ken Galbraith
CHM | Chairman | 63 | 05/01/2022 |
Susan Mahony
BRD | Director/Board Member | 61 | 01/06/2019 |
Kelvin Neu
BRD | Director/Board Member | 52 | 01/03/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/9/26 A | Exercice | Chief Technology Officer | 87,906 | 0.1239% | ||
| 7/6/26 A | Free | Chief Operating Officer | 939 | 0.0013% | ||
| 5/13/26 A | Free | EVP, General Counsel | 297,000 | 0.4027% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.69% | +12.96% | +62.63% | +331.89% | 2.01B | |
| -3.10% | -3.43% | +36.29% | +67.69% | 65.28B | |
| +0.33% | +7.26% | +11.51% | +77.95% | 54.57B | |
| +0.16% | +3.69% | +8.39% | +101.27% | 53.59B | |
| -0.75% | +2.13% | +23.14% | +47.25% | 45.03B | |
| -1.30% | -1.11% | +17.77% | +120.71% | 42.17B | |
| +1.26% | +2.23% | +241.81% | +835.31% | 39.42B | |
| -0.74% | -4.84% | +14.53% | +44.45% | 32.71B | |
| -2.70% | -7.34% | +23.17% | +0.36% | 24.01B | |
| +1.11% | +17.90% | +56.87% | +47.78% | 26.5B | |
| Average | -0.41% | +2.89% | +49.61% | +167.47% | 38.53B | |
| Weighted average by Cap. | -0.72% | +1.77% | +45.25% | +149.60% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 293M 263M 243M 221M 412M 27.87B 417M 2.92B 1.16B 14.61B 1.1B 1.08B 46.33B | 371M 333M 308M 279M 522M 35.28B 528M 3.69B 1.47B 18.49B 1.39B 1.36B 58.64B |
| Net income | 65.19M 58.51M 54.02M 48.99M 91.56M 6.19B 92.69M 648M 257M 3.25B 245M 239M 10.29B | 113M 101M 93.37M 84.67M 158M 10.7B 160M 1.12B 445M 5.61B 423M 414M 17.79B |
| Net Debt | -246M -221M -204M -185M -346M -23.39B -350M -2.45B -971M -12.26B -924M -904M -38.87B | -301M -270M -249M -226M -423M -28.57B -428M -2.99B -1.19B -14.98B -1.13B -1.11B -47.5B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/10/26 | $28.85 | +1.69% | 1,125,675 |
| 26/10/26 | $28.37 | +0.53% | 833,942 |
| 23/10/26 | $28.22 | -0.77% | 1,123,557 |
| 22/10/26 | $28.44 | +1.16% | 757,349 |
| 21/10/26 | $28.12 | +4.48% | 1,318,869 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ZYME Stock
Select your edition
All financial news and data tailored to specific country editions
